Pharma News for the week of Sept. 7, 2020

 

The perception of the politization of the FDA has had a negative impact amongst the public and thus has impacted people willingness to get a vaccine any time soon. In a recent poll by the Kaiser Family Foundation “health tracking poll”, many Americans are worried about the safety of a vaccine that might be released before the presidential election in November due to what they consider President Trump’s undue influence in the FDA’s mission. According to the poll, 54% of respondents wouldn’t get a vaccine if it were released before the election because of safety concerns and the belief that it was rushed to help President Trump win in November. (Forbes)

The African Union and Novartis have announced an agreement that would facilitate the acquisition and disbursement of a COVID-19 vaccine when it becomes available. This is good news considering there is a lot of concern that richer countries have been buying future doses of a vaccine in tremendous quantities while poorer countries have been pushed aside in their attempts to protect their people. (Worldpharmanews)

Florida has cut ties with a Quest Diagnostics after the company has admitted that they missed reporting the results of 75,000 COIVD-19 tests, some dating back as far as April. Quest plans to release the finds in a single day which would throw off the data that state health officials use to monitor COVID-19 around the state. This announcement comes on the heels of Quest admitting the same issue in California, essentially invalidating the tests taken during the same time period. (NPR)

Calling delivering the vaccine to 7.8 billion people the largest transportation challenge ever, the International Air Transport Association (IATA) has asked governments around the world to begin planning how they are going to deliver a COVID-19 vaccine when it becomes available. According to the IATA delivering one dose to the world’s population will require 8,000 jumbo jets filled to capacity. (CNBC)

CEOs of nine pharmaceutical companies have pledged to wait to release a vaccine until phase 3 trials are over and the science says that the vaccine is safe. The White House has hinted that they might grant emergency authorization to get a vaccine out to the public before the November presidential election. (Biopharmadive)

en_USEnglish
en_USEnglish